Research & Markets: Immunotherapy in Oncology Drug Pipeline Update 2015: 641 companies plus partners developing 1064 cancer i...
January 26 2015 - 05:06AM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/hnmwj3/immunotherapy_in)
has announced the addition of the "Immunotherapy in Oncology Drug
Pipeline Update 2015" report to their offering.
Cancer immunotherapy offers an attractive therapeutic addition,
delivering treatment of high specificity, low toxicity and
prolonged activity. In this Drug Pipeline Update the author brings
together the fields of antibodies, vaccines, and immunostimulators
in oncology drug development into one source.
There are today 641 companies plus partners developing 1064
cancer immunotherapy drugs in 2994 developmental projects in
cancer. In addition, there are 19 suspended drugs and the
accumulated number of ceased drugs over the last years amount to
another 563 drugs.
Immunotherapy In Oncology Drug Pipeline Update lists all drugs
and gives you a progress analysis on each one of them. Identified
drugs are linked to 481 different targets. All included targets
have been cross-referenced for the presence of mutations associated
with human cancer. To date 430 out of the 436 studied drug targets
so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations
and links out to the mutational analysis for each of the drug
targets for detailed information. All drugs targets are further
categorized on in the software application by 71 classifications of
molecular function and with pathway referrals to BioCarta, KEGG,
NCI-Nature and NetPath.
For more information visit
http://www.researchandmarkets.com/research/hnmwj3/immunotherapy_in
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Oncology